


Bliretrigine

Cat. No.:	HY-145558		
CAS No.:	1233229-75-8		
Molecular Formula:	C ₂₀ H ₂₄ N ₄ O ₂		
Molecular Weight:	352.43		
Target:	Sodium Channel		
Pathway:	Membrane Transporter/Ion Channel		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (141.87 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM		2.8374 mL	14.1872 mL	28.3744 mL
		5 mM		0.5675 mL	2.8374 mL	5.6749 mL
10 mM			0.2837 mL	1.4187 mL	2.8374 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.09 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.09 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	Bliretrigine is a sodium channel blocker. Bliretrigine has the effect of relieving pain ^{[1][2][3]} .
-------------	----------------------------------------------------------------------------------------------------------------

REFERENCES

- [1]. WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022.
- [2]. Yoshihiro OYAMADA, et al. External medicinal preparation containing N2-([1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl)-L-alanineamide for treating and/or preventing peripheral neuropathic pain. Patent AU2019306705.

[3]. Hironori Kinoshita, et al. Preparation of N2-[(benzimidazol-2-yl or imidazo[4,5-b]pyridin-2-yl)methyl]amino acid amide derivatives as inhibitors of sensory neuron specific sodium channel (SNS). Patent AU2009331179.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA